Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Ronan W Hsieh, Steven Borson, Anastasia Tsagianni, Dan P Zandberg, Ronan W Hsieh, Steven Borson, Anastasia Tsagianni, Dan P Zandberg

Abstract

Head and neck cancer is the 6th most common cancer worldwide with the most common histology being squamous cell carcinoma (HNSCC). While the majority of patients present at a stage where curative intent therapy is possible, when patients recur and/or develop metastatic disease, outcomes are generally poor, especially with systemic therapy alone, and they lag behind other solid tumors. Over the last decade immunotherapy has revolutionized the field of oncology, and anti-PD-1-based therapy has changed the standard of care in recurrent/metastatic (R/M) HNSCC as well. With these gains have come new questions to continue to move the field forward. In this review, we discuss the tumor immune microenvironment and predictive biomarkers and current status and future directions for immunotherapy in recurrent/metastatic head and neck cancer.

Keywords: HNSCC; PD-1; PD-L1; head and neck cancer; immunotherapy; metastatic; recurrent; systemic therapy.

Conflict of interest statement

DZ received research support (institutional) for his role as principal investigator on trials with Merck, BMS, Macrogenics, Astrazeneca, Bicara, Lilly, Aduro, GSK, Checkmate pharmaceuticals. DZ served on an advisory board for Bluprint Medicines and Macrogenics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Hsieh, Borson, Tsagianni and Zandberg.

Figures

Figure 1
Figure 1
Predictors of the Tumor Immune Microenvironment in HNSCC.

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA: Cancer J Clin (2011) 61(2):69–90. 10.3322/caac.20107
    1. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. . Human Papillomavirus and Survival of Patients With Oropharyngeal Cancer. N Engl J Med (2010) 363(1):24–35. 10.1056/NEJMoa0912217
    1. Dunn GP, Old LJ, Schreiber RD. The Three Es of Cancer Immunoediting. Annu Rev Immunol (2004) 22:329–60. 10.1146/annurev.immunol.22.012703.104803
    1. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic Cells Pulsed With RNA Are Potent Antigen-Presenting Cells In Vitro and In Vivo . J Exp Med (1996) 184(2):465–72. 10.1084/jem.184.2.465
    1. Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT. A Chemokine Expressed in Lymphoid High Endothelial Venules Promotes the Adhesion and Chemotaxis of Naive T Lymphocytes. Proc Natl Acad Sci USA (1998) 95(1):258–63. 10.1073/pnas.95.1.258
    1. Franciszkiewicz K, Boissonnas A, Boutet M, Combadiere C, Mami-Chouaib F. Role of Chemokines and Chemokine Receptors in Shaping the Effector Phase of the Antitumor Immune Response. Cancer Res (2012) 72(24):6325–32. 10.1158/0008-5472.CAN-12-2027
    1. Mellman I, Coukos G, Dranoff G. Cancer Immunotherapy Comes of Age. Nature (2011) 480(7378):480–9. 10.1038/nature10673
    1. Chen DS, Mellman I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity (2013) 39(1):1–10. 10.1016/j.immuni.2013.07.012
    1. Ferris RL, Hunt JL, Ferrone S. Human Leukocyte Antigen (HLA) Class I Defects in Head and Neck Cancer: Molecular Mechanisms and Clinical Significance. Immunol Res (2005) 33(2):113–33. 10.1385/IR:33:2:113
    1. Albers A, Abe K, Hunt J, Wang J, Lopez-Albaitero A, Schaefer C, et al. . Antitumor Activity of Human Papillomavirus Type 16 E7-Specific T Cells Against Virally Infected Squamous Cell Carcinoma of the Head and Neck. Cancer Res (2005) 65(23):11146–55. 10.1158/0008-5472.CAN-05-0772
    1. Lopez-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, et al. . Role of Antigen-Processing Machinery in the In Vitro Resistance of Squamous Cell Carcinoma of the Head and Neck Cells to Recognition by CTL. J Immunol (2006) 176(6):3402–9. 10.4049/jimmunol.176.6.3402
    1. Hathaway B, Landsittel DP, Gooding W, Whiteside TL, Grandis JR, Siegfried JM, et al. . Multiplexed Analysis of Serum Cytokines as Biomarkers in Squamous Cell Carcinoma of the Head and Neck Patients. Laryngoscope (2005) 115(3):522–7. 10.1097/01.mlg.0000157850.16649.b8
    1. Young MR, Wright MA, Lozano Y, Matthews JP, Benefield J, Prechel MM. Mechanisms of Immune Suppression in Patients With Head and Neck Cancer: Influence on the Immune Infiltrate of the Cancer. Int J Cancer (1996) 67(3):333–8. 10.1002/(SICI)1097-0215(19960729)67:3<333::AID-IJC5>;2-S
    1. Duffey DC, Chen Z, Dong G, Ondrey FG, Wolf JS, Brown K, et al. . Expression of a Dominant-Negative Mutant Inhibitor-Kappabalpha of Nuclear factor-kappaB in Human Head and Neck Squamous Cell Carcinoma Inhibits Survival, Proinflammatory Cytokine Expression, and Tumor Growth In Vivo . Cancer Res (1999) 59(14):3468–74.
    1. Zou W. Regulatory T Cells, Tumour Immunity and Immunotherapy. Nat Rev Immunol (2006) 6(4):295–307. 10.1038/nri1806
    1. Ryden SE, Oberman HA. Compatibility of Common Intravenous Solutions With CPD Blood. Transfusion (1975) 15(3):250–5. 10.1046/j.1537-2995.1975.15375160360.x
    1. Saito T, Kuss I, Dworacki G, Gooding W, Johnson JT, Whiteside TL. Spontaneous Ex Vivo Apoptosis of Peripheral Blood Mononuclear Cells in Patients With Head and Neck Cancer. Clin Cancer Res (1999) 5(6):1263–73.
    1. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, et al. . Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells. J Immunol (2009) 182(9):5693–701. 10.4049/jimmunol.0900092
    1. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. . PD-L1 Is a Novel Direct Target of HIF-1alpha, and Its Blockade Under Hypoxia Enhanced MDSC-Mediated T Cell Activation. J Exp Med (2014) 211(5):781–90. 10.1084/jem.20131916
    1. Adducci JE. Chorioangioma of the Placenta Causing Fetal Distress. Minn Med (1975) 58(11):820–1.
    1. Wheeler SE, Shi H, Lin F, Dasari S, Bednash J, Thorne S, et al. . Enhancement of Head and Neck Squamous Cell Carcinoma Proliferation, Invasion, and Metastasis by Tumor-Associated Fibroblasts in Preclinical Models. Head Neck (2014) 36(3):385–92. 10.1002/hed.23312
    1. Messent AJ, Tuckwell DS, Knauper V, Humphries MJ, Murphy G, Gavrilovic J. Effects of Collagenase-Cleavage of Type I Collagen on Alpha2beta1 Integrin-Mediated Cell Adhesion. J Cell Sci (1998) 111(Pt 8):1127–35. 10.1242/jcs.111.8.1127
    1. Egeblad M, Werb Z. New Functions for the Matrix Metalloproteinases in Cancer Progression. Nat Rev Cancer (2002) 2(3):161–74. 10.1038/nrc745
    1. Pai SI, Zandberg DP, Strome SE. The Role of Antagonists of the PD-1:PD-L1/PD-L2 Axis in Head and Neck Cancer Treatment. Oral Oncol (2016) 61:152–8. 10.1016/j.oraloncology.2016.08.001
    1. Chen L. Co-Inhibitory Molecules of the B7-CD28 Family in the Control of T-Cell Immunity. Nat Rev Immunol (2004) 4(5):336–47. 10.1038/nri1349
    1. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. . Tumor-Associated B7-H1 Promotes T-Cell Apoptosis: A Potential Mechanism of Immune Evasion. Nat Med (2002) 8(8):793–800. 10.1038/nm730
    1. Saada-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, et al. . Hyperprogression During Anti-PD-1/PD-L1 Therapy in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Ann Oncol (2017) 28(7):1605–11. 10.1093/annonc/mdx178
    1. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and Its Ligands in Tolerance and Immunity. Annu Rev Immunol (2008) 26:677–704. 10.1146/annurev.immunol.26.021607.090331
    1. Boussiotis VA. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med (2016) 375(18):1767–78. 10.1056/NEJMra1514296
    1. Ritprajak P, Azuma M. Intrinsic and Extrinsic Control of Expression of the Immunoregulatory Molecule PD-L1 in Epithelial Cells and Squamous Cell Carcinoma. Oral Oncol (2015) 51(3):221–8. 10.1016/j.oraloncology.2014.11.014
    1. Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, et al. . Interferon Regulatory Factor-1 Is Prerequisite to the Constitutive Expression and IFN-Gamma-Induced Upregulation of B7-H1 (Cd274). FEBS Lett (2006) 580(3):755–62. 10.1016/j.febslet.2005.12.093
    1. Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, et al. . Association of PD-L1 Overexpression With Activating EGFR Mutations in Surgically Resected Nonsmall-Cell Lung Cancer. Ann Oncol (2014) 25(10):1935–40. 10.1093/annonc/mdu242
    1. Qian Y, Deng J, Geng L, Xie H, Jiang G, Zhou L, et al. . TLR4 Signaling Induces B7-H1 Expression Through MAPK Pathways in Bladder Cancer Cells. Cancer Invest (2008) 26(8):816–21. 10.1080/07357900801941852
    1. Zhang F, Liu Z, Cui Y, Wang G, Cao P. [The Clinical Significance of the Expression of Costimulatory Molecule PD-L1 in Nasopharyngeal Carcinoma]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2008) 22(9):408–10.
    1. Zandberg DP, Strome SE. The Role of the PD-L1:PD-1 Pathway in Squamous Cell Carcinoma of the Head and Neck. Oral Oncol (2014) 50(7):627–32. 10.1016/j.oraloncology.2014.04.003
    1. Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, et al. . Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma. Cancer Res (2013) 73(6):1733–41. 10.1158/0008-5472.CAN-12-2384
    1. Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD. Relationship Between the Expressions of PD-L1 and Tumor-Infiltrating Lymphocytes in Oral Squamous Cell Carcinoma. Oral Oncol (2011) 47(12):1148–53. 10.1016/j.oraloncology.2011.08.007
    1. Hsu MC, Hsiao JR, Chang KC, Wu YH, Su IJ, Jin YT, et al. . Increase of Programmed Death-1-Expressing Intratumoral CD8 T Cells Predicts a Poor Prognosis for Nasopharyngeal Carcinoma. Mod Pathol (2010) 23(10):1393–403. 10.1038/modpathol.2010.130
    1. Ukpo OC, Thorstad WL, Lewis JS, Jr. B7-H1 Expression Model for Immune Evasion in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma. Head Neck Pathol (2013) 7(2):113–21. 10.1007/s12105-012-0406-z
    1. Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, et al. . B7-H1 Blockade Augments Adoptive T-Cell Immunotherapy for Squamous Cell Carcinoma. Cancer Res (2003) 63(19):6501–5.
    1. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. . Specific Recruitment of Regulatory T Cells in Ovarian Carcinoma Fosters Immune Privilege and Predicts Reduced Survival. Nat Med (2004) 10(9):942–9. 10.1038/nm1093
    1. Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 Blockade Reverses the Suppression of Melanoma Antigen-Specific CTL by CD4+ CD25(Hi) Regulatory T Cells. Int Immunol (2009) 21(9):1065–77. 10.1093/intimm/dxp072
    1. Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. . Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors. Cancer Discov (2013) 3(12):1355–63. 10.1158/1535-7163.TARG-13-B290
    1. Chen L, Flies DB. Molecular Mechanisms of T Cell Co-Stimulation and Co-Inhibition. Nat Rev Immunol (2013) 13(4):227–42. 10.1038/nri3405
    1. Liao P, Wang H, Tang YL, Tang YJ, Liang XH. The Common Costimulatory and Coinhibitory Signaling Molecules in Head and Neck Squamous Cell Carcinoma. Front Immunol (2019) 10:2457. 10.3389/fimmu.2019.02457
    1. Mandal R, Senbabaoglu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, et al. . The Head and Neck Cancer Immune Landscape and Its Immunotherapeutic Implications. JCI Insight (2016) 1(17):e89829. 10.1172/jci.insight.89829
    1. Saloura V, Izumchenko E, Zuo Z, Bao R, Korzinkin M, Ozerov I, et al. . Immune Profiles in Primary Squamous Cell Carcinoma of the Head and Neck. Oral Oncol (2019) 96:77–88. 10.1016/j.oraloncology.2019.06.032
    1. Cillo AR, Kurten CHL, Tabib T, Qi Z, Onkar S, Wang T, et al. . Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. Immunity (2020) 52(1):183–99.e9. 10.1016/j.immuni.2019.11.014
    1. Wondergem NE, Nauta IH, Muijlwijk T, Leemans CR, van de Ven R. The Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: On Subsets and Subsites. Curr Oncol Rep (2020) 22(8):81. 10.1007/s11912-020-00938-3
    1. Wagner S, Wittekindt C, Reuschenbach M, Hennig B, Thevarajah M, Wurdemann N, et al. . CD56-Positive Lymphocyte Infiltration in Relation to Human Papillomavirus Association and Prognostic Significance in Oropharyngeal Squamous Cell Carcinoma. Int J Cancer (2016) 138(9):2263–73. 10.1002/ijc.29962
    1. Chen X, Yan B, Lou H, Shen Z, Tong F, Zhai A, et al. . Immunological Network Analysis in HPV Associated Head and Neck Squamous Cancer and Implications for Disease Prognosis. Mol Immunol (2018) 96:28–36. 10.1016/j.molimm.2018.02.005
    1. Balermpas P, Rodel F, Rodel C, Krause M, Linge A, Lohaus F, et al. . CD8+ Tumour-Infiltrating Lymphocytes in Relation to HPV Status and Clinical Outcome in Patients With Head and Neck Cancer After Postoperative Chemoradiotherapy: A Multicentre Study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer (2016) 138(1):171–81. 10.1002/ijc.29683
    1. Partlova S, Boucek J, Kloudova K, Lukesova E, Zabrodsky M, Grega M, et al. . Distinct Patterns of Intratumoral Immune Cell Infiltrates in Patients With HPV-Associated Compared to Non-Virally Induced Head and Neck Squamous Cell Carcinoma. Oncoimmunology (2015) 4(1):e965570. 10.4161/21624011.2014.965570
    1. Saloura V, Zhixiang Z, Koeppen H, Keck M, Khattri A, Boe M, et al. . Correlation of T-Cell Inflamed Phenotype With Mesenchymal Subtype, Expression of PD-L1, and Other Immune Checkpoints in Head and Neck Cancer. J Clin Oncol (2014) 32:5s, 2014 (suppl; abstr 6009). 10.1200/jco.2014.32.15_suppl.6009
    1. Hladikova K, Koucky V, Boucek J, Laco J, Grega M, Hodek M, et al. . Tumor-Infiltrating B Cells Affect the Progression of Oropharyngeal Squamous Cell Carcinoma via Cell-to-Cell Interactions With CD8(+) T Cells. J Immunother Cancer (2019) 7(1):261. 10.1186/s40425-019-0726-6
    1. Russell S, Angell T, Lechner M, Liebertz D, Correa A, Sinha U, et al. . Immune Cell Infiltration Patterns and Survival in Head and Neck Squamous Cell Carcinoma. Head Neck Oncol (2013) 5(3):24.
    1. Desrichard A, Kuo F, Chowell D, Lee KW, Riaz N, Wong RJ, et al. . Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas. J Natl Cancer Institute (2018) 110(12):1386–92. 10.1093/jnci/djy060
    1. Zandberg DP, Menk AV, Velez M, Normolle D, DePeaux K, Liu A, et al. . Tumor Hypoxia Is Associated With Resistance to PD-1 Blockade in Squamous Cell Carcinoma of the Head and Neck. J Immunother Cancer (2021) 9(5). 10.1136/jitc-2020-002088
    1. Brooks JM, Menezes AN, Ibrahim M, Archer L, Lal N, Bagnall CJ, et al. . Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer. Clin Cancer Res: An Off J Am Assoc Cancer Res (2019) 25(17):5315–28. 10.1158/1078-0432.CCR-18-3314
    1. Watermann C, Pasternack H, Idel C, Ribbat-Idel J, Bragelmann J, Kuppler P, et al. . Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion. Clin Cancer Research: an Off J Am Assoc Cancer Res (2021) 27(2):632–44. 10.1158/1078-0432.CCR-20-0197
    1. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. . Platinum-Based Chemotherapy Plus Cetuximab in Head and Neck Cancer. N Engl J Med (2008) 359(11):1116–27. 10.1056/NEJMoa0802656
    1. Saloura V, Cohen EE, Licitra L, Billan S, Dinis J, Lisby S, et al. . An Open-Label Single-Arm, Phase II Trial of Zalutumumab, a Human Monoclonal Anti-EGFR Antibody, in Patients With Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck. Cancer Chemother Pharmacol (2014) 73(6):1227–39. 10.1007/s00280-014-2459-z
    1. Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, Licitra L, et al. . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med (2016) 375(19):1856–67. 10.1056/NEJMoa1602252
    1. Harrington KJ, Ferris RL, Blumenschein G, Jr., Colevas AD, Fayette J, Licitra L, et al. . Nivolumab Versus Standard, Single-Agent Therapy of Investigator’s Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 141): Health-Related Quality-of-Life Results From a Randomised, Phase 3 Trial. Lancet Oncol (2017) 18(8):1104–15. 10.1016/S1470-2045(17)30421-7
    1. Cohen EEW, Soulieres D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. . Pembrolizumab Versus Methotrexate, Docetaxel, or Cetuximab for Recurrent or Metastatic Head-and-Neck Squamous Cell Carcinoma (KEYNOTE-040): A Randomised, Open-Label, Phase 3 Study. Lancet (2019) 393(10167):156–67. 10.1016/S0140-6736(18)31999-8
    1. Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, Licitra L, et al. . Nivolumab vs Investigator’s Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: 2-Year Long-Term Survival Update of CheckMate 141 With Analyses by Tumor PD-L1 Expression. Oral Oncol (2018) 81:45–51. 10.1016/j.oraloncology.2018.04.008
    1. Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, et al. . Durvalumab With or Without Tremelimumab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: EAGLE, a Randomized, Open-Label Phase III Study. Ann Oncol (2020) 31(7):942–50. 10.1016/j.annonc.2020.04.001
    1. Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G, Jr., et al. . Pembrolizumab Alone or With Chemotherapy Versus Cetuximab With Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-048): A Randomised, Open-Label, Phase 3 Study. Lancet (2019) 394(10212):1915–28. 10.1016/S0140-6736(19)32591-7
    1. Burtness B, Rischin D, Greil R, Soulieres D, Tahara M, Castro G, et al. . Efficacy of First-Line (1L) Pembrolizumab by PD-L1 Combined Positive Score <1, 1-19, and ≥20 in Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): KEYNOTE-048 Subgroup Analysis [Abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research, vol. 80. Philadelphia (PA: AACR; Cancer Res; ) (2020). p. Abstract nr LB–258.
    1. Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, et al. . Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol: Off J Am Soc Clin Oncol (2018) 36(14):1412–8. 10.1200/JCO.2017.77.0388
    1. Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, et al. . Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. J Clin Oncol: Off J Am Soc Clin Oncol (2017) 35(36):4050–6. 10.1200/JCO.2017.73.3675
    1. Kao H, Ang M, Ng QS, Tan DSW, Tan W, Rajasekaran T, et al. . Combination Ipilimumab and Nivolumab in Recurrent/Metastatic Nasopharyngeal Carcinoma (R/M NPC): Updated Efficacy and Safety Analysis of NCT03097939. Ann Oncol (2020) 31(suppl_6):S1347–54. 10.1016/j.annonc.2020.10.260
    1. Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. . Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol (2016) 34(32):3838–45. 10.1200/JCO.2016.68.1478
    1. Ferris RL, Blumenschein G, Jr., Harrington K, Fayette J, Guigay J, Colevas AD, et al. . Tumor-Associated Immune Cell PD-L1 Expression and Peripheral Immune Profiling: Analyses From CheckMate 141. In: Annual Meeting, vol. #CT021. (2017).
    1. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. . IFN-Gamma-Related mRNA Profile Predicts Clinical Response to PD-1 Blockade. J Clin Invest (2017) 127(8):2930–40. 10.1172/JCI91190
    1. Prat A, Navarro A, Pare L, Reguart N, Galvan P, Pascual T, et al. . Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Res (2017) 77(13):3540–50. 10.1158/0008-5472.CAN-16-3556
    1. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. . Safety and Clinical Activity of Pembrolizumab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-012): An Open-Label, Multicentre, Phase 1b Trial. Lancet Oncol (2016) 17(7):956–65. 10.1016/S1470-2045(16)30066-3
    1. Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, et al. . Predicting Response to Checkpoint Inhibitors in Melanoma Beyond PD-L1 and Mutational Burden. J Immunother Cancer (2018) 6(1):32. 10.1186/s40425-018-0344-8
    1. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. . Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. New Engl J Med (2014) 371(23):2189–99. 10.1056/NEJMoa1406498
    1. Seiwert TY, Haddad R, Bauml J, Weiss J, Pfister D, Gupta S, et al. . Biomarkers Predictive of Response to Pembrolizumab in Head and Neck Cancer (HNSCC). In: Abstract LB-339 Presented at: American Association for Cancer Research Annual Meeting. Chicago: (2018). p. 2018.
    1. Zandberg DP, Velez M, Menk AV, Liu A, Skinner H, Duvvuri U, et al. . The Impact of Tumor Hypoxia on the Clinical Efficacy of Anti-PD-1 mAb Treatment in Recurrent/Metastatic HNSCC Patients (R/M). J Clin Oncol (2020) 38(15_suppl):6546–6. 10.1200/JCO.2020.38.15_suppl.6546
    1. Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, et al. . Frameshift Events Predict Anti-PD-1/L1 Response in Head and Neck Cancer. JCI Insight (2018) 3(4). 10.1172/jci.insight.98811
    1. Ferris RL, Blumenschein GR, Jr, Harrington K, Fayette J, Guigay J, Colevas AD, et al. . (2017). Abstract CT022: Evaluation of Oral Microbiome Profiling as a Response Biomarker in Squamous Cell Carcinoma of the Head and Neck: Analyses From CheckMate 141, in: Proceedings of the American Association for Cancer Research Annual Meeting 2017, 2017 Apr 1-5, Vol. 77. p. Abstract nr CT022 2017. Washington, DC Philadelphia (PA: AACR; Cancer Res; ).
    1. Fakhry C, Zhang Q, Nguyen-Tan PF, Rosenthal D, El-Naggar A, Garden AS, et al. . Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol (2014) 32(30):3365–73. 10.1200/JCO.2014.55.1937
    1. Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, et al. . Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol: Off J Am Soc Clin Oncol (2017) 35(14):1542–9. 10.1200/JCO.2016.70.1524
    1. Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, et al. . Durvalumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results From a Single-Arm, Phase II Study in Patients With >/=25% Tumour Cell PD-L1 Expression Who Have Progressed on Platinum-Based Chemotherapy. Eur J Cancer (2019) 107:142–52. 10.1016/j.ejca.2018.11.015
    1. Park JC, Durbeck J, Boudadi K, Ho WJ, Kang H. The Efficacy of Anti-PD-1 Immune Checkpoint Inhibitor in Nasopharyngeal Carcinoma. Oral Oncol (2020) 108:104935. 10.1016/j.oraloncology.2020.104935
    1. Wildsmith S, Scott M, Midha A, Barker C, Whiteley J, Ratcliffe M, et al. . PD-L1 Expression in Patients Screened for Phase 2 Head and Neck Squamous Cell Carcinoma Clinical Studies (HAWK and CONDOR). In: AACR Annual Meeting 2018, Poster Presentation #5530. (2018).
    1. Hamoir M, Schmitz S, Suarez C, Strojan P, Hutcheson KA, Rodrigo JP, et al. . The Current Role of Salvage Surgery in Recurrent Head and Neck Squamous Cell Carcinoma. Cancers (Basel) (2018) 10(8). 10.3390/cancers10080267
    1. Sato H, Okonogi N, Nakano T. Rationale of Combination of Anti-PD-1/PD-L1 Antibody Therapy and Radiotherapy for Cancer Treatment. Int J Clin Oncol (2020) 25(5):801–9. 10.1007/s10147-020-01666-1
    1. Zandberg DP, Diwanji T, Morales RE, Tyer T, J S, Engelman A, et al. . Phase II Trial of Reirradiation (ReRT) Plus Pembrolizumab for Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN): Analysis of Early Toxicity. Poster Presentation SITC Annual Meeting 2018. J Immunother Cancer (2018) 6(Suppl 1):P302. 2018.
    1. Janot F, de Raucourt D, Benhamou E, Ferron C, Dolivet G, Bensadoun RJ, et al. . Randomized Trial of Postoperative Reirradiation Combined With Chemotherapy After Salvage Surgery Compared With Salvage Surgery Alone in Head and Neck Carcinoma. J Clin Oncology: Off J Am Soc Clin Oncol (2008) 26(34):5518–23. 10.1200/JCO.2007.15.0102
    1. Wise-draper T, Haque S, Steele A, Desai S, Harris T, Riaz MK, et al. . Interim Analysis of a Single Arm Phase 2 Study of Adjuvant Nivolumab After Salvage Resection in Head and Neck Squamous Cell Carcinoma Patients Previously Treated With Definitive Therapy. Ann Oncol (2019) 30(suppl_5):v449–74. 10.1093/annonc/mdz252.2019
    1. Cohen EE, Ferris RL, Psyrri A, Haddad R, Tahara M, Bourhis J, et al. . Primary Results of the Phase III JAVELIN Head & Neck 100 Trial: Avelumab Plus Chemoradiotherapy (CRT) Followed by Avelumab Maintenance vs CRT in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN). Ann Oncol (2020) 31(suppl_4):S599–628. 10.1016/annonc/annonc277.2020
    1. Angevin E, Groenland S, Lim AM, Liberal J, Moreno V, Trigo J, et al. . Updated Analysis of the Inducible T-Cell Co-Stimulatory Receptor (ICOS) Agonist, GSK3359609 (GSK609), Combination With Pembrolizumab (PE) in Patients (Pts) With Anti-PD-1/L1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma (HNSCC). J Clin Oncol (2020) 2020(suppl; abstr 6517):38. 10.1200/JCO.2020.38.15_suppl.6517
    1. Aggarwal C, Joshua AM, Ferris RL, Antonia S, Rahma O, Tolcher A, et al. . A Phase 1, Open-Label, Dose-Escalation Study of Enoblituzumab in Combination With Pembrolizumab in Patients With Select Solid Tumors. J Immunother Cancer (2018) 6(Suppl 1):2018.
    1. Zandberg DP, Ferris RL, Laux D, Mehra R, Nabell L, J K, et al. . A Phase II Study of ADU-S100 in Combination With Pembrolizumab in Adult Patients With PD-L1+ Recurrent or Metastatic HNSCC: Preliminary Safety, Efficacy and PK/PD Results. Ann Oncol (2020) 31(suppl_7):S1441–51. 10.1016/annonc/annonc392.2020
    1. Kirkwood JM, Milhem M, Zakharia Y. Durable Responses in Anti-PD-1 Refractory Melanoma Following Intratumoral Injection of Toll-Like Receptor 9 (TLR9) Agonist CMP-001, in Combination With Pembrolizumab. In: Presented at: 2019 Annual Meeting of the Society for Immunotherapy of Cancer November 6-10, 2019. National Harbor, MD: (2019).
    1. Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, Chai-Ho W, et al. . Pembrolizumab Plus Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-Label, Multi-Arm, Non-Randomised, Multicentre, Phase 2 Trial. Clin Trial Lancet Oncol (2021) 22(6):883-92. 10.1016/S1470-2045(21)00136-4
    1. Chung CH, Bonomi M, Steuer C, Schell M, Jiannnong L, Johnson M, et al. . Concurrent Cetuximab (CTX) and Nivolumab (NIVO) in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Results of Phase II Study. J Clin Oncol (2020) 38(15_suppl):6515–5. 10.1200/JCO.2020.38.15_suppl.6515
    1. cohen RB, Bauman J, Salas S, Colevas AD, Even C, Cupissol D, et al. . Combination of Monalizumab and Cetuximab in Recurrent or Metastatic Head and Neck Cancer Patients Previously Treated With Platinum-Based Chemotherapy and PD-(L)1 Inhibitors. J Clin Oncol (2020) 38(15_suppl):6516–6. 10.1200/JCO.2020.38.15_suppl.6516
    1. Papa S, Adami A, Metoudi M, Achkova D, Schalkwyk M, Pereira A, et al. . Abstract CT118: T4 Immunotherapy of Head and Neck Squamous Cell Carcinoma Using Pan-ErbB Targeted CAR T-Cells. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017, vol. 77. Washington, DC Philadelphia (PA: AACR; Cancer Res; (2017).
    1. Jimeno A, Papa S, Haigentz M, Jr, Rodriguez-Moreno J, Schardt J, Fardis M, et al. . (2020). Safety and Efficacy of Tumor Infiltrating Lymphocytes (TIL; LN-145) in Combination With Pembrolizumab for Advanced, Recurrent or Metastatic HNSCC, In: Poster in Head and Neck Cancer at SITC Annual Meeting, , November 9-14, 2020, Vol. Abstract 353.
    1. Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, et al. . Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes. J Clin Oncol: Off J Am Soc Clin Oncol (2005) 23(35):8942–9. 10.1200/JCO.2005.02.6195
    1. Smith C, Tsang J, Beagley L, Chua D, Lee V, Li V, et al. . Effective Treatment of Metastatic Forms of Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma With a Novel Adenovirus-Based Adoptive Immunotherapy. Cancer Res (2012) 72(5):1116–25. 10.1158/0008-5472.CAN-11-3399
    1. Chia WK, Teo M, Wang WW, Lee B, Ang SF, Tai WM, et al. . Adoptive T-Cell Transfer and Chemotherapy in the First-Line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma. Mol Ther: J Am Soc Gene Ther (2014) 22(1):132–9. 10.1038/mt.2013.242
    1. Doran SL, Stevanovic S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, et al. . T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-In-Human, Phase I/II Study. J Clin Oncol: Off J Am Soc Clin Oncol (2019) 37(30):2759–68. 10.1200/JCO.18.02424
    1. Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary S, Meyer TJ, Lack JB, et al. . TCR-Engineered T Cells Targeting E7 for Patients With Metastatic HPV-Associated Epithelial Cancers. Nat Med (2021) 27(3):419–25. 10.1038/s41591-020-01225-1
    1. Wu Y, Deng Z, Wang H, Ma W, Zhou C, Zhang S. Repeated Cycles of 5-Fluorouracil Chemotherapy Impaired Anti-Tumor Functions of Cytotoxic T Cells in a CT26 Tumor-Bearing Mouse Model. BMC Immunol (2016) 17(1):29. 10.1186/s12865-016-0167-7
    1. Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM. Enhancing Antitumor Response by Combining Immune Checkpoint Inhibitors With Chemotherapy in Solid Tumors. Ann Oncol: Off J Eur Soc Med Oncol/ESMO (2019) 30(2):219–35. 10.1093/annonc/mdy551

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅